BBNX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Beta Bionics, Inc. Common Stock · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 12.83 USD
-19.1% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -3.6% below the Trend Line and sits at 16.9% of its 52-week range. The latest completed week returned -19.1%, after a -23.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: earnings are due in 2d.

Setup score 31 out of 100
Latest Close 12.83 USD 31 Jul 2026
1W Return -19.1% latest completed week
4W Return -23.4% short-term follow-through
12W Return 33.0% quarterly tape
Trend Breadth 40.4% 21 of 52 weeks active
Volume Ratio 1.8x vs 13-week average
What is working
  • The trend backdrop is active with a 1-week active streak.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.27% based on similar historical setup states.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -19.1% Latest completed week; four-week move -23.4%. Indicator stack 26/69 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.27% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 52/100 conviction; expected move 16.4%. News sentiment 54/100 46 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -3.6% below the Trend Line and sits at 16.9% of its 52-week range. The latest completed week returned -19.1%, after a -23.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3912-week average 0.16

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.39Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -23.4% over four weeks, 33.0% over 12 weeks, and -21.8% over one year. The current trend has remained active for 1 consecutive weeks.

Performance by holding period

1W-19.1%
4W-23.4%
12W33.0%
26W-7.2%
52W-21.8%
Active trend streak1 weeks
Active weeks in one year21
Trend breadth40.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.04Latest activity-pressure read.
Pressure change7.7%Four-week change in activity pressure.
Leadership-35.23Latest relative-leadership reading.
RS change-85.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value24/100Relative valuation strength. Underlying universe rank 77; rank 1 is best.
Quality9/100Profitability and accounting quality. Underlying universe rank 92; rank 1 is best.
Momentum32/100Medium-term price momentum. Underlying universe rank 69; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
6.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
57.2%
Gross profit retained from each unit of revenue.
Operating margin
-60.3%
Operating profit retained from revenue.
Free-cash-flow margin
-43.9%
Free cash flow generated from revenue.
Return on invested capital
-20.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
57.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-29.7%
Net share repurchases relative to market value.
Shareholder yield
-29.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

BBNX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 16.4%, and Sharemaestro trend signal active.

Conviction52/100
Expected move16.4%
Put/call volume0.00
Pressure100
Speculation4
Volatility88
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment54/100

Weighted news tone is neutral across 46 relevant articles.

9 positive · 35 neutral · 2 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move16.4%Nearest-chain priced movement where available.
52-week drawdown-60.8%Distance below the 52-week high.
13-week volatility11.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+46.5%Week of 17 Apr.
Worst week-19.1%Week of 31 Jul.
Latest week-19.1%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses4
Sharp losses11
Recent vol11.6%13-week weekly-return volatility.
Base vol13.6%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew11.7% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape32/100

Trend, activity pressure, participation, and risk combine to a 32/100 tape read.

 Indicator analysis33/100

Latest 12-week confirmation: trend 1/12, activity pressure 9/12, relative leadership 0/12.

Activity pressure 0.39; No reversal markers Next-Week ExpectancyNegative 43.27%

Next-week expectancy is negative with a 43.27% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors16/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93; Small Cap Core rank 83 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options35/100

BBNX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 16.4%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 16.4% Sentiment54/100

Weighted news tone is neutral across 46 relevant articles.

Beta Bionics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-07-31 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202612.83 USD-19.1%13.31 USD17.19 USD1.04-35.238.4MOn
24 Jul 202615.85 USD-8.3%13.86 USD17.25 USD1.10-20.145.1MOff
17 Jul 202617.29 USD1.5%14.39 USD17.26 USD1.18-14.456.2MOff
10 Jul 202617.03 USD1.6%14.79 USD17.26 USD0.99-19.214.0MOff
3 Jul 202616.76 USD-0.4%15.22 USD17.27 USD0.97-19.033.0MOff
26 Jun 202616.82 USD21.2%15.64 USD17.27 USD0.92-18.086.4MOff
19 Jun 202613.88 USD-4.5%16.12 USD17.28 USD0.63-35.604.5MOff
12 Jun 202614.53 USD4.6%16.71 USD17.33 USD0.50-31.485.7MOff
5 Jun 202613.89 USD14.6%17.13 USD17.37 USD0.22-33.695.0MOff
29 May 202612.12 USD2.5%17.54 USD17.42 USD-0.01-45.332.4MOff
22 May 202611.82 USD24.9%18.05 USD17.49 USD-0.12-45.734.2MOff
15 May 20269.46 USD-2.0%18.35 USD17.58 USD-0.15-56.373.5MOff
8 May 20269.65 USD-6.2%18.70 USD17.70 USD-0.10-56.033.0MOff
1 May 202610.29 USD-7.9%19.08 USD17.82 USD-0.38-51.003.9MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.